Avanos Medical Inc. Common Stock (AVNS)
FairStock Score: 57/100 — STEADY
Key Financials
| Current Price | $24.99 |
| Market Cap | $1.2B |
| P/E Ratio | -15.62 |
| ROE | -9.18% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I approach Avanos as a medical device company with necessary products but unproven economics. In the 2026-Q1 period, the supplied figures show revenue of $182.2 million, net income of $5.1 million, and a 2.80% net margin. That is real profit, but thin. Trailing EPS is -$1.60, so at the 2026-07-24 close of $24.99 the FairStock-calculated P/E is -15.62. The P/B is 1.49, offering some asset support, but ROE is -9.18% and ROCE is only 0.95%, which tells me the business is not earning attractive returns on capital. Debt is modest at D/E 0.18, a genuine positive, yet FCF is just $7.5 million TTM, a 0.7% FCF yield. Piotroski 5/9 and Altman 1.96 suggest middling financial momentum and some balance-sheet caution. Revenue growth of 0.72% is flat; profit growth of 99.67% is striking but likely off a low base. The stock is near the top of its $10.64-$25.49 52-week range, with beta 1.57. FairStock score 57/100 and no Lynch category because only 0 years of filed results are available. I see no clear durable competitive advantage in these numbers, and without durable revenue growth and better cash generation, the current price lacks a margin of safety.
In plain English: Avanos Medical makes feeding tubes and pain-relief devices used in hospitals and home care. The business looks weak right now: sales are barely growing, profits are thin, and it lost money over the past year. At about $25 a share, near the high end of its yearly range, the price looks full compared with those results.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-07-24 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer